17,261 trials
Rhinitis, Allergic, Seasonal
Primary: Mean Messenger Ribonucleic Acid (mRNA) Concentrations as a Measure of Gene Expression — 2625.5; 2987.2; 3134.2; 3162.0 COPIES/50 nanogram (NG) — p=0.1351
Mild Cognitive Impairment (MCI)
Primary: Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI — -0.1203; 0.4353; -0.2238…
Non-Hodgkins Lymphoma
Primary: Overall Response Rate — 31 Percentage of participants
Sepsis
Primary: Serum Levels of IL-6, IL-10 and TNFα — 28; 16; 9.3; 6.3 pg/mL
COPD
Primary: Airway Blood Flow Reactivity (Delta Qaw) — 29.1; 13.7; 8.9; 15.6 % of change
Cannabis Dependence
Primary: Change in Marijuana Use — -1.7 days
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Response — 0; 10; 1; 0 Participants
Head and Neck Cancer
Primary: Progression-free Survival at 2 Years — 75.9 percentage of participants
Hepatitis C Infection
Primary: Undetectable HCV RNA — 0; 1 participants
Lymphoma · Leukemia · Multiple Myeloma
Primary: Number of Participants DLT in Arm 1 in Dose Escalation Phase — 0; 0; 2; 1 Participants
Nicotine Dependence
Primary: Cigarettes Per Day — 15.7; 14.3; 9.8; 5.3 cigarettes per day — p=0.0004
Malignant Neoplasm
Primary: Grade 3-4 Acute GVHD — 0.21 probability
Opioid Abuse · Opioid Dependence
Primary: Drug Self-administration Breakpoint — 347; 363; 1472; 43 Clicks on a computer mouse
Vestibular Schwannoma · Neurofibromatosis Type 2
Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response
Diabetes Mellitus, Type 2
Primary: Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE) or Death — 12; 9; 1; 0 Participants